Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share capital and treasury holdings.
- Shares Purchased: 590,000 Ordinary Shares on May 29, 2013.
- Price Range: Highest price paid was 1,765.0 pence per share; lowest was 1,727.5 pence per share.
- Treasury Holdings (Settled): 501,492,012 shares (9.24% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,159,012 shares (10.21% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,927,270,135 shares.
Material Changes
The primary material change reported is the increase in treasury shares following the purchase of 590,000 shares on May 29, 2013. This transaction increased the total treasury holding percentage from 9.24% to 10.21% of total voting rights when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,927,270,135) to calculate accurate ownership percentages under Disclosure and Transparency Rules.
- Confirm the settlement status of the 590,000 shares purchased on May 29, 2013, to distinguish between settled and unsettled treasury holdings.
- Note that the company intends to hold the repurchased shares in Treasury rather than retiring them immediately.